CSO Lindsay Davies Co-Chairs ISCT Europe 2024 Meeting

September 3, 2024

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), a leader in advanced cell therapy and immunotherapy research, is proud to announce that Dr. Lindsay Davies, the company’s Chief Scientific Officer (CSO) and ISCT Europe Regional Secretary, serves as Co-Chair together with Dr. Massimiliano Gnecchi of the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden, from September 4-6.

"We are thrilled to have Dr. Davies representing NextCell Pharma at such an influential event," says Mathias Svahn, CEO of NextCell Pharma AB. "Her expertise in cell therapy and her leadership within ISCT underscore our company's commitment to advancing the science and therapeutic potential of cell-based treatments. This meeting is a great opportunity to showcase the progress NextCell is making in the field of advanced therapies, in particular the 5-year efficacy data with a single infusion of ProTrans for treatment of type-1 diabetes."

The ISCT Europe 2024 Regional Meeting brings together leading researchers, clinicians, and industry professionals from around the world to discuss the latest advances and challenges in the field of cell and gene therapy. This prestigious event focuses on cutting-edge scientific breakthroughs, regulatory trends, and innovative approaches to translating research into clinical applications, aiming to accelerate the development of new therapies for patients.

Dr. Lindsay Davies, in her dual role as CSO of NextCell Pharma AB and ISCT Europe Regional Secretary, has played a pivotal role in organizing the event and will be involved heavily with and steering the discussions during the event. Her leadership has been instrumental in shaping the program, which features high-profile speakers and interactive sessions addressing the most pressing issues in the rapidly evolving field of regenerative medicine.

The ISCT Europe 2024 Regional Meeting covers a wide range of topics, including innovations in stem cell therapies, gene editing technologies, regulatory hurdles, and strategies for commercialization. The event provides a platform for collaboration among industry leaders, academic institutions, and regulatory bodies to further the development of next-generation therapies aimed at treating chronic diseases and those indications with unmet medical needs.

NextCell Pharma AB continues to be at the forefront of cell therapy development with its lead product candidate ProTrans, a mesenchymal stromal cell-based therapy designed to treat autoimmune diseases such as type 1 diabetes. The company remains dedicated to pushing the boundaries of regenerative medicine through scientific innovation, clinical research, and partnerships with leading organizations in the biotech sector.

About ISCT

The International Society for Cell and Gene Therapy (ISCT) is a global association with a focus on driving the translation of scientific research into clinical applications of cell and gene therapies. With over 1,700 members in 50+ countries, ISCT connects academic, regulatory, and commercial stakeholders to advance the field of regenerative medicine.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.

Download attachment Read full press release on Cision (external link)

2021-10-06

NextCell invited speaker at the Advanced Therapy Congress in London

Today, NextCell Pharma AB’s CEO, Dr. Mathias Svahn, is presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies. Ranked as one of Europe's most important events in the field of advanced therapies, the ExCel event brings together leading players in the pharmaceutical industry to provide information on the latest technologies attracting more than 2,000 visitors. The scope of the summit is to explore, define and tackle the challenges of, and patient access to ATMPs (Advanced Therapy Medicinal Products), as the field moves into an exciting 2022. NextCell has developed an

Read more Read more

2021-09-09

All patients in the low-dose group treated with ProTrans

NextCell Pharma AB ("NextCell" or the "Company") announces that three patients with Covid-19 have now been treated with ProTrans in the Swedish study ProTrans19+SE conducted at Örebro University Hospital. As a result, all patients in the low-dose cohort are now treated. The full title of the study is: "Treatment of Respiratory Complications Associated with COVID-19 Infection with Wharton's Jelly (WJ) -Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): An Open Phase IB Clinical Trial", (EudraCT 2020-002078-29). NextCell sponsors the study, which will include a total of nine patients

Read more Read more

2021-08-17

NextCell files patent application for treatment of COVID-19 with ProTrans

NextCell Pharma AB ("NextCell" or the "Company”) announces that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions. The latest patent application has is entitled; "Allogeneic Composition for Treatment off Covid-19". By using the possibility of priority from a previous application, the COVID-19 application has a priori day of August 14, 2020, i.e. dated 1 year back in time. NextCell has filed a

Read more Read more

2021-07-30

NextCell Pharma publishes Interim Report 3 2020/2021

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2020 - February 28, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. Third quarter (2020-03-01 until 2021-05-31) · Operating income amounted to SEK 905 750 (750 512). · Operating result amounted to SEK -6 457 514 (-4 833 332). · Earnings

Read more Read more

2021-06-22

NextCell enters CAR-T joint venture

NextCell Pharma AB (“NextCell”) today announces a joint venture together with their long-term collaborator and contract manufacture organisation, Polski Bank Komórek Macierzystych (PBKM, FamiCord Group). NextCell has acquired ~10 % of shares in the newly started company FamiCordTx through a directed equity issue, raising the capital with 0,5 MEuro in cash. FamiCordTx has exclusively licensed a patent pending CAR-T technology and the tech transfer is completed, and the production of CAR-T cell therapy is awaiting ATMP manufacturing approval before production of CAR-T for clinical trial use can

Read more Read more

2021-06-17

Advisory meeting with the European Medicines Agency

NextCell Pharma AB (“NextCell” or “the Company”) announces that a scientific advisory meeting with the European Medicines Agency (EMA) has been held regarding ProTrans and the path forward to a possible market approval. The focus was the design of the phase III study ProTrans-3, which NextCell intends to submit an application for later this year.

Read more Read more

2021-06-10

COVID-19 patient treated with ProTrans

NextCell Pharma AB (“NextCell” or “the Company”) announces that the first patient with severe pneumonia, as a result of COVID-19 infection, has now been treated with ProTrans. The patient was hospitalized at Örebro University Hospital, where the phase 1b study ProTrans19+SE is in progress led by Principal Investigator Associate Professor Josefin Sundh. NextCell's drug candidate, ProTrans, is an immune- balancing cell therapy for the treatment of autoimmune diseases and inflammatory conditions. Patients with severe pneumonia as a result of by SARS-CoV-2 infection are at risk of rapid

Read more Read more

2021-06-08

Article about Gene and Cell Therapy

Professor Edvard Smith, CMO NextCell Pharma AB ("NextCell" or the "Company") has written a review article in the Swedish Medical Journal (Läkartidningen) entitled "Gene therapy now comes in many medical specialties", together with Associate Professor Pontus Blomberg, Director of Operations; both at the Department of Laboratory Medicine, Karolinska Institutet; Karolinska Centre for Cell Therapy, Karolinska University Hospital, Stockholm. The main message of the article is that the development of gene therapy has been rapid, and more and more preparations are reaching patients and in many

Read more Read more